{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:15:49Z","timestamp":1771330549001,"version":"3.50.1"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jdcr.2023.09.038","type":"journal-article","created":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T01:31:45Z","timestamp":1697333505000},"page":"45-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Letter in response to the case report \u201cTopical ruxolitinib in the treatment of refractory facial seborrheic dermatitis\u201d"],"prefix":"10.1016","volume":"42","author":[{"given":"Meron","family":"Teklu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Jin","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2023.09.038_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jdcr.2022.04.003","article-title":"Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis","volume":"24","author":"Pope","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"16","key":"10.1016\/j.jdcr.2023.09.038_bib2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jdcr.2023.09.038_bib3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2023.09.038_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.jdcr.2023.09.038_bib5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2133.2001.04082.x","article-title":"Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators\u00a0in the skin by immunohistochemistry","volume":"144","author":"Faergemann","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdcr.2023.09.038_bib6","article-title":"Ruxolitinib cream has dual efficacy on pruritus and inflammation in experimental dermatitis","volume":"11","author":"Scuron","year":"2020","journal-title":"Front Immunol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512623003855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512623003855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:25:55Z","timestamp":1762475155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512623003855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":6,"alternative-id":["S2352512623003855"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.09.038","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter in response to the case report \u201cTopical ruxolitinib in the treatment of refractory facial seborrheic dermatitis\u201d","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.09.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}